Clinical Trial

Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients

Study acronym: CESAR
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Phase III, open label, randomised, multicentre, blind for evaluators clinical trial to evaluate the efficacy of esketamine nasal spray at flexible dosis compared to aripiprazole in elderly participants (\>60 years) who suffer from treatment-resistant major depressive
Trial Details
NCT Number NCT07153406
Lead Sponsor Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions Depressive Disorder
Enrollment 220 participants
Start Date 2025-09-15
Primary Completion 2026-09-15 (estimated)
Study Completion 2029-01-15 (estimated)
Updated on ClinicalTrials.gov 2025-09-04